Respiratory drug pipeline

Asthma, COPD, cystic fibrosis, idiopathic pulmonary fibrosis, and related respiratory therapeutics.

Recent approvals (last 30 days)

No approvals in this window.

Upcoming PDUFA dates (next 6 months)

No upcoming decisions in this window.

Top sponsors

1. GlaxoSmithKline · 96 drugs
2. AstraZeneca · 64 drugs
3. Chiesi Farmaceutici S.p.A. · 54 drugs
4. · 36 drugs
5. Teva Branded Pharmaceutical Products R&D, Inc. · 24 drugs
6. Pearl Therapeutics, Inc. · 16 drugs
7. Organon and Co · 15 drugs
8. Sumitomo Pharma America, Inc. · 12 drugs
9. Vertex Pharmaceuticals Incorporated · 11 drugs
10. Henan University of Traditional Chinese Medicine · 10 drugs

Key drug classes

• Inhaled corticosteroid · 53
• Inhaled corticosteroid/long-acting beta-2 agonist combination · 42
• Long-acting beta-2 agonist (LABA) · 35
• Corticosteroid · 28
• Inhaled corticosteroid/long-acting beta-2 agonist combination (ICS/LABA) · 24
• Long-acting muscarinic antagonist (LAMA) · 17
• Beta-2 adrenergic agonist (short-acting) · 14
• Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination · 11
• Inhaled corticosteroid (ICS) · 9
• Leukotriene receptor antagonist · 9
• Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) · 9
• PDE4 inhibitor · 9
• Beta-2 adrenergic receptor agonist · 8
• Recombinant enzyme · 8
• Short-acting beta-2 agonist (SABA) · 8

Major diseases in this area

• asthma
• copd
• cystic fibrosis

Subscribe

Get respiratory approvals + PDUFA dates in your RSS reader:

• Respiratory RSS feed · Atom · JSON

Other therapeutic areas